Scarica l'app Stockscreener
4.81
0.42%
0.02
Dopo l'orario di chiusura:
4.72
-0.09
-1.87%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.79
Aprire:
$4.81
Volume 24 ore:
126.13K
Relative Volume:
0.44
Capitalizzazione di mercato:
$200.08M
Reddito:
$2.00M
Utile/perdita netta:
$109.16M
Rapporto P/E:
1.8618
EPS:
2.5835
Flusso di cassa netto:
$-9.11M
1 W Prestazione:
+7.37%
1M Prestazione:
+19.65%
6M Prestazione:
+49.38%
1 anno Prestazione:
+133.50%
Intervallo 1D:
$4.75
$4.88
Intervallo di 1 settimana:
$4.44
$4.94
Portata 52W:
$2.0601
$5.19
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Nome
Oramed Pharmaceuticals Inc
Settore
Industria
Telefono
646-844-1164
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.81 | 199.25M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-09 | Iniziato | National Securities | Buy |
| 2020-12-03 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-11 | Iniziato | Aegis Capital | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-12-11 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Reiterato | FBR Capital | Outperform |
| 2015-12-01 | Reiterato | H.C. Wainwright | Buy |
| 2015-11-19 | Iniziato | FBR Capital | Outperform |
| 2015-04-13 | Ripresa | MLV & Co | Buy |
| 2014-01-30 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Iniziato | MLV & Co | Buy |
| 2013-12-03 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Oramed Pharmaceuticals Inc Borsa (ORMP) Ultime notizie
Oramed Pharmaceuticals Incorporated Actuals & Estimates (TRADEGATE:OJU1) - TradingView
Top Penny Stocks To Watch In August 2026 - simplywall.st
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayDividend Earnings Report - Vinanet
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine
Nano Dimension Appoints Nadav Kidron to Lead Capital Allocation Review - citybiz
Oramed CEO Joins Nano Dimension Board as Directors Weigh Capital Options - Stock Titan
MSN Money - MSN
ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A - Stock Titan
Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results - marketbeat.com
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a shareEarnings Preview - TradingView
Oramed: Q2 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 2Q 2026: Revenue $0 Net income $78.16M, EPS $1.84— 10-Q Summary - TradingView
Oramed Pharmaceuticals (NASDAQ: ORMP) pivots to investment model with $116M profit - Stock Titan
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oramed Pharmaceuticals (ORMP) Projected to Release Quarterly Earnings on Thursday - marketbeat.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
Oramed Pharmaceuticals (ORMP) Holds Steady at $4.33 as Range-Bound Trading PersistsRounding Bottom - vinanet.vn
ORMP | Oramed Pharmaceuticals Inc. Executive Compensation - Quiver Quantitative
ORMP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oramed Pharmaceuticals announces annual shareholder meeting - Bitget
ORAMED PHARMACEUTICALS INC. SEC Filing (Aug 3, 2026) | ORMP ARS - Stock Titan
Oramed Pharmaceuticals Shows Modest Uptick, Testing Resistance at $4.33Rip Sell Trade - vinanet.vn
Oramed Pharmaceuticals Market Sentiment - Benzinga
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Cash Flow - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Balance Sheet - TradingKey
ORMP Q4 2025 Earnings: EPS Surges Past Estimates Despite Revenue Absence, Stock Declines 3.13%Earnings Forecast Report - dars.gov.et
ORMP|Oramed Pharmaceuticals Inc|Price:4.762|Chg%:+0.192 - TradingKey
Oramed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:ORMP - TradingView
TradingKey - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oramed Pharmaceuticals Inc (OJU1.SG) stock price, news, quote and history - Yahoo Finance UK
Nano Dimension Ltd. (NASDAQ: NNDM) sees Oramed stake drop to 3.3% - Stock Titan
AlTi Global Leads Our Selection Of 3 Promising Penny Stocks - simplywall.st
Oramed Pharmaceuticals (ORMP) Posts Slight Uptick as Stock Consolidates Near Key SupportJurik MA - vinanet.vn
Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback - Ad-hoc-news.de
Oramed Pharmaceuticals Q4 2025 Earnings: EPS Surprise Driven by Non-Operating Gains; Stock Slips Despite BeatLong-Term Guidance - vinanet.vn
Oramed Pharmaceuticals Inc. Net Worth (2026) - GuruFocus
Price to sales forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects - Ad-hoc-news.de
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet - AOL.com
Oramed Pharmaceuticals outlines its oral drug strategy as Nasdaq-listed biotech pursues long-term gr - Ad Hoc News
ORMP Q4 2025 Earnings: Positive EPS Surprise Despite Revenue Absence, Stock Falls 5.91%Analyst Drop Coverage - dars.gov.et
Price to earnings forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Price to book forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals stock holds its ground. Investors await the next company update. - ad-hoc-news.de
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
Oramed Pharmaceuticals Inc Azioni (ORMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):